IRLAB Therapeutics AB
IRLAB discovers and develops a portfolio of transformative therapies targeting all stages of Parkinson’s disease. Mesdopetam (IRL790), under development for the treatment of levodopa-induced dyskinesia, has completed Phase IIb and is being prepared for Phase III. Pirepemat (IRL752) is currently in Phase IIb and is









